An early phase study of an EGFRvIII peptide based vaccine in patients with EGFRvIII expressing cancers.

Trial Profile

An early phase study of an EGFRvIII peptide based vaccine in patients with EGFRvIII expressing cancers.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2015

At a glance

  • Drugs Hemocyanin; Rindopepimut; Sargramostim
  • Indications Gastric cancer; Ovarian cancer; Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Jul 2012 Actual end date (November 2008) added as reported by ClinicalTrials.gov record.
    • 04 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top